New developments in invasive fungal disease.
Invasive fungal infections continue to be a major cause of morbidity and mortality in immunocompromised or severely ill patients. This report highlights new research data presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy on invasive fungal disease and its treatment. A number of important clinical trials were reported, and there were also interesting presentations on the use of new diagnostic tools, further studies on therapeutic drug monitoring for azoles and updates on several of the emerging fungal pathogens.
Universitätsklinikum Münster, Albert-Schweitzer-St, 33 48149 Münster, Germany. andreash.groll@ukmuenster.de
Andreas H
AH
Groll
Joanna
J
Lumb
D000666:Amphotericin B / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D001393:Azoles / Q000494:pharmacology; D015415:Biomarkers / Q000032:analysis; D002986:Clinical Trials as Topic; D021821:Communicable Diseases, Emerging / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D003226:Congresses as Topic; D019937:Diagnostic Techniques and Procedures / Q000295:instrumentation; D016903:Drug Monitoring / Q000379:methods; D025141:Drug Resistance, Fungal; D006801:Humans; D016867:Immunocompromised Host; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology
D001393:Azoles; D015415:Biomarkers; D000666:Amphotericin B